Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Nanopore Sequencing-based Pharmacogenomic Panel to Personalize Tuberculosis Drug Dosing.

American journal of respiratory and critical care medicine - 15 Jun 2024

Verma Renu, da Silva Kesia Esther, Rockwood Neesha, Wasmann Roeland E, Yende Nombuso, Song Taeksun, Kim Eugene, Denti Paolo, Wilkinson Robert J, Andrews Jason R

Abstract excerpt

Rationale: Standardized dosing of antitubercular drugs leads to variable plasma drug levels, which are associated with adverse drug reactions, delayed treatment response, and relapse. Mutations in genes affecting drug metabolism explain considerable interindividual pharmacokinetic variability; however, pharmacogenomic assays that predict metabolism of antitubercular drugs have been lacking. Objectives: We sought...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antitubercular Agents
Share to Isoniazid

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Nanopore Sequencing

Share to Pharmacogenomic Testing

Share to Precision Medicine

Share to Rifampin

Share to South Africa

Share to Tuberculosis

Source

Open in PubMed Open full text

Identifiers

PMID: 38647526
DOI: 10.1164/rccm.202309-1583OC
PMCID: PMC11208962

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Nanopore Sequencing-based Pharmacogenomic Panel to Personalize Tuberculosis Drug Dosing.PMID 38647526Read ↗

A Nanopore sequencing-based pharmacogenomic panel to personalize tuberculosis drug dosingSemantic proximity Read ↗

A rapid pharmacogenomic assay to detect <i>NAT2</i> polymorphisms and guide isoniazid dosing for tuberculosis treatmentSemantic proximity Read ↗

A Rapid Pharmacogenomic Assay to Detect NAT2 Polymorphisms and Guide Isoniazid Dosing for Tuberculosis Treatment.Semantic proximity Read ↗

Rapid and economical drug resistance profiling with Nanopore MinION for clinical specimens with low bacillary burden of Mycobacterium tuberculosisSemantic proximity Read ↗

Pharmacogenetic Study of Drugs Affecting Mycobacterium tuberculosis.Semantic proximity Read ↗

Compact Targeted Next-Generation Sequencing for Rapid Diagnosis of Drug-Resistant Tuberculosis using Minimum BiocontainmentSemantic proximity Read ↗

Nanopore-based targeted sequencing test for direct tuberculosis identification, genotyping, and detection of drug resistance mutations: a side-by-side comparison of targeted next-generation sequencing technologies.Semantic proximity Read ↗

Development and Assessment of a Novel Whole-Gene-Based Targeted Next-Generation Sequencing Assay for Detecting the Susceptibility of Mycobacterium tuberculosis to 14 DrugsSemantic proximity Read ↗

Genomic Sequencing from Sputum for Tuberculosis Disease Diagnosis, Lineage Determination, and Drug Susceptibility PredictionSemantic proximity Read ↗

A Rapid Drug Resistance Genotyping Workflow for Mycobacterium tuberculosis, Using Targeted Isothermal Amplification and Nanopore Sequencing.Semantic proximity Read ↗

Genetic polymorphisms and adverse reactions to antituberculosis therapySemantic proximity Read ↗

Rapid Identification of Drug-Resistant Tuberculosis Genes Using Direct PCR Amplification and Oxford Nanopore Technology SequencingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.